Diabetic Gastroparesis Efficacy/Safety Study of TZP-102

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered for 12 weeks, in diabetic subjects with symptoms associated with gastroparesis.
Epistemonikos ID: b2d433eedea372f75f0b3612603ee209e3d7ccf4
First added on: May 11, 2024